Effects of Lumacaftor-Ivacaftor Therapy on CFTR Function in Phe508del Homozygous Patients with Cystic Fibrosis

S. Gräber (Heidelberg, Germany), C. Dopfer (Hannover, Germany), L. Naehrlich (Giessen, Germany), L. Gyulumyan (Hannover, Germany), H. Scheuermann (Heidelberg, Germany), S. Hirtz (Heidelberg, Germany), S. Wege (Heidelberg, Germany), H. Mairbaeurl (Heidelberg, Germany), M. Dorda (Hannover, Germany), R. Hyde (Hannover, Germany), A. Bagheri-Hanson (Giessen, Germany), C. Rueckes-Nilges (Giessen, Germany), S. Fischer (Hannover, Germany), M. Mall (Heidelberg, Germany), B. Tuemmler (Hannover, Germany)

Source: International Congress 2018 – Latest developments in cystic fibrosis
Session: Latest developments in cystic fibrosis
Session type: Poster Discussion
Number: 3415
Disease area: Paediatric lung diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Gräber (Heidelberg, Germany), C. Dopfer (Hannover, Germany), L. Naehrlich (Giessen, Germany), L. Gyulumyan (Hannover, Germany), H. Scheuermann (Heidelberg, Germany), S. Hirtz (Heidelberg, Germany), S. Wege (Heidelberg, Germany), H. Mairbaeurl (Heidelberg, Germany), M. Dorda (Hannover, Germany), R. Hyde (Hannover, Germany), A. Bagheri-Hanson (Giessen, Germany), C. Rueckes-Nilges (Giessen, Germany), S. Fischer (Hannover, Germany), M. Mall (Heidelberg, Germany), B. Tuemmler (Hannover, Germany). Effects of Lumacaftor-Ivacaftor Therapy on CFTR Function in Phe508del Homozygous Patients with Cystic Fibrosis. 3415

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effects of Telerehabilitation on Peripheral Muscle Function in Pediatric Cystic Fibrosis Patients During Covid-19 Pandemic
Source: Virtual Congress 2021 – Physical activity, exercise training and (tele)rehabilitation in respiratory patients
Year: 2021


Cystic Fibrosis Patients Eligible for Modulator Drugs: Data from Cystic Fibrosis Registry of Turkey
Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis
Year: 2019

Does physiotherapy affect Lung Clearance Index in Cystic Fibrosis patients ?
Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research
Year: 2018

Phenotypic Analysis of a Ferret Model of Cystic Fibrosis
Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease
Year: 2009

The Effects Of Respiratory Viruses on The Acute Pulmonary Exacerbations In Cystic Fibrosis Patients
Source: International Congress 2019 – Insights into paediatric bronchology
Year: 2019


Natural Variability of Clinically Measured Lung Clearance Index in Children with Cystic Fibrosis
Source: Virtual Congress 2021 – Monitoring of lung disease and CFTR function in children with cystic fibrosis
Year: 2021



Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020


Impact of Anemia On Clinically Stable Adult Non-cystic Fibrosis Bronchiectasis
Source: International Congress 2018 – Management of bronchiectasis and large airway diseases
Year: 2018


Bacterial Contamination of Home Nebulizers in Children with Cystic Fibrosis and Clinical Implication on the Number of Pulmonary Exacerbations
Source: International Congress 2019 – Infection and inflammation in cystic fibrosis
Year: 2019


Cystic Fibrosis: Clinical profile of 10 patients with R334W mutation compared to ?F508 homozigoty
Source: Virtual Congress 2020 – Cystic fibrosis
Year: 2020


Nasal Nitric Oxide Sampling In 0-5-year-old Patients With Cystic Fibrosis, Primary Ciliary Dyskinesia and Healthy Controls
Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function
Year: 2021

Microbiome in Cystic Fibrosis Exacerbations
Source: ERS Lung Science Conference 2019
Year: 2019

Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis
Year: 2020


A new Humanized Mouse Model for Idiopathic Pulmonary Fibrosis and Effects of Nintedanib Treatment
Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Year: 2018



Polymorphisms in NOS-1 and NOS-3 genes may influence the cystic fibrosis severity?
Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology
Year: 2014

HspB5 in Cystic Fibrosis
Source: International Congress 2018 – Latest developments in cystic fibrosis
Year: 2018



Prognostic Factors in Patients with Idiopathic Pulmonary Fibrosis; Evaluation using Quantitative CT Analysis of Fibrosis and Emphysema
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019


Single nucleotide polymorphims 1540G/A, 2694T/G and 4521G/A of CFTR gene and their association with cystic fibrosis phenotype
Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology
Year: 2014

Dynamic Balance, Exercise Capacity and Muscle Oxygenation in Children with Non Cystic Fibrosis Bronchiectasis
Source: Virtual Congress 2020 – Tapas of respiratory physiotherapy
Year: 2020


Cystic Fibrosis in Iran
Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis
Year: 2019